Parkside Financial Bank & Trust’s AbCellera Biologics ABCL Stock Holding History

Parkside Financial Bank & Trust’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-200	Closed	-$686	–	2708
2025 Q2	$686	Hold	200	–	–	﹤0.01%	2391
2025 Q1	$446	Hold	200	–	–	﹤0.01%	2476
2024 Q4	$586	Hold	200	–	–	﹤0.01%	1843
2024 Q3	$520	Hold	200	–	–	﹤0.01%	1827
2024 Q2	$592	Hold	200	–	–	﹤0.01%	1740
2024 Q1	$906	Hold	200	–	–	﹤0.01%	1639
2023 Q4	$1.14K	Buy	+200	New	+$927	﹤0.01%	1589

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Parkside Financial Bank & Trust's ABCL Position: Q3 2025 in Review

Parkside Financial Bank & Trust sold out of AbCellera Biologics (ABCL) in Q3 2025, closing a stake of 200 shares — an estimated $686 sold.

Parkside Financial Bank & Trust first reported a position in ABCL in Q4 2023 and held it in 7 quarters. The position peaked at $1.14K in Q4 2023. 141 funds tracked by Wall St. Rank hold ABCL as of Q3 2025.

Parkside Financial Bank & Trust reported no remaining AbCellera Biologics position as of Q3 2025 after selling out during the quarter.
Parkside Financial Bank & Trust sold 200 AbCellera Biologics shares in Q3 2025, an estimated $686.
Parkside Financial Bank & Trust first reported a position in AbCellera Biologics in Q4 2023 and held it in 7 quarters.
Parkside Financial Bank & Trust's AbCellera Biologics position peaked at $1.14K in Q4 2023.
141 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2025.

Based on Parkside Financial Bank & Trust's 13F filing for Q3 2025, filed 30 Oct 2025.